Nivolumab for unresectable cutaneous epithelial malignancies - an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1)
Favorite
Share
More Options
13

Open in WPS to view all 13 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
